Skip to main content
OpenTrials
Completed

NCT Number: NCT07268586

Intravenous Atropine in Reducing Reperfusion Arrhythmias, Conduction Abnormalities and Hypotension in Inferior ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

People with acute inferior wall myocardial infarction will be given an intravenous drug called atropine that increases the heart rate to check if it prevents heart rhythm disturbances during performing coronary intervention

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myocardial Infarction Cardiovascular Diseases Heart Diseases Infarction Ischemia Myocardial Ischemia Necrosis Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Ain Shams University

Cairo, Abbasia, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Acute inferior ST elevation myocardial infarction

Exclusion criteria

  • Execution of rescur percutaneous coronary intervention after thrombolysis
  • Mechanical complications or no reflow or spontaneous reperfusion.
  • Prior implantation of permanent or temporary pacemakers
  • History of bradycardia, hypotension or ventricular tachycardia with a definitive cause (unrelated to the disease under study)
  • Prior coronary artery bypass graft surgery
  • Atropine contraindications Unwillingness to participate in the

Treatment and study plan

Intravenous atropine immediately before wire crossing during primary percutaneous coronary intervention

Drug

Intravenous atropine 1 mg immediately before wire crossing during primary percutaneous coronary intervention

Intravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention

Drug

Intravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention

Primary outcomes

  1. Conduction abnormalities

    Time frame: Periprocedurally

    Occurrence of conduction abnormalities

  2. Reperfusion arrhythmias

    Time frame: Periprocedurally

    Occurrence of reperfusion arrhythmias

Secondary outcomes

  1. Major adverse cardiac events

    Time frame: Periprocedurally

    Inhospital major adverse cardiac events including all-cause mortality, cardiovascular mortality, stroke and myocardial infarction

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 8, 2025
Registry last updated
Mar 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.